Lacosamide Neuraxpharm (Lacosamide)

• Lacosamide is indicated for the treatment of focal seizure disorders as part of an adjunctive therapy regimen.
• Partial‑onset seizures: Decreases seizure frequency as add‑on therapy.
• Focal seizures with secondary generalization: Improves overall seizure control when combined with other antiseizure drugs.
• Epilepsy patients requiring adjunctive treatment: Enhances seizure management in individuals whose seizures are not adequately controlled by a single medication.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyper‑excitability. It also binds to collapsin response mediator protein‑2 (CRMP2), modulating neuronal signaling pathways involved in seizure propagation.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness
• Headache
• Nausea
• Fatigue
• Blurred vision
• Diplopia

Serious or Rare Side Effects

• Cardiac arrhythmia (PR interval prolongation)
• Suicidal ideation
• Severe skin reactions (e.g., Stevens‑Johnson syndrome)
• Hypersensitivity reactions
• Elevated liver enzymes
• Respiratory depression

• When prescribing Lacosamide, clinicians should observe several safety considerations.
• Cardiac monitoring: Assess baseline ECG and monitor for PR interval prolongation.
• Renal impairment: Adjust dosing in patients with severe renal dysfunction.
• Hepatic dysfunction: Use caution in patients with liver disease; monitor liver enzymes.
• Concomitant CNS depressants: Observe for additive sedation or respiratory depression.
• Pregnancy and lactation: Evaluate risk‑benefit; limited data available.
• Store at ambient temperature: Keep below 25 °C, retain in original container, protect from moisture.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital) may reduce Lacosamide levels.
• Co‑administration with other sodium‑channel blockers may increase risk of CNS depression.
• Drugs that prolong PR interval (e.g., class I antiarrhythmics) may cause cardiac effects.

Moderate Interactions (Monitor Closely)

• CYP2C19 inhibitors (e.g., fluoxetine) may increase Lacosamide concentrations.
• Alcohol may enhance dizziness and sedation.
• Other antiseizure medications may require dose adjustments.
• Antihypertensives may have additive hypotensive effect.
• Anticholinergic agents may increase anticholinergic burden.